BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with weakness, fatigue, sarcopenia, and reduced quality of life (QoL). Black men have a higher incidence and mortality from PCa than Caucasians. We hypothesized that despite ADT, strength training (ST) would increase muscle power and size, thereby improving body composition, physical function, fatigue levels, and QoL in older black men with PCa. METHODS: Muscle mass, power, strength, endurance, physical function, fatigue perception, and QoL were measured in 17 black men with PCa on ADT before and after 12 weeks of ST. Within-group differences were determined using t tests and regression models. RESULTS: ST significantly increased total body muscle mass (2.7%), thigh muscle volume (6.4%), power (17%), and strength (28%). There were significant increases in functional performance (20%), muscle endurance (110%), and QoL scores (7%) and decreases in fatigue perception (38%). Improved muscle function was associated with higher functional performance (R (2) = 0.54) and lower fatigue perception (R (2) = 0.37), and both were associated with improved QoL (R (2) = 0.45), whereas fatigue perception tended to be associated with muscle endurance (R (2) = 0.37). CONCLUSIONS: ST elicits muscle hypertrophy even in the absence of testosterone and is effective in counteracting the adverse functional consequences of ADT in older black men with PCa. These improvements are associated with reduced fatigue perception, enhanced physical performance, and improved QoL. Thus, ST may be a safe and well-tolerated therapy to prevent the loss of muscle mass, strength, and power commonly observed during ADT.
BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with weakness, fatigue, sarcopenia, and reduced quality of life (QoL). Black men have a higher incidence and mortality from PCa than Caucasians. We hypothesized that despite ADT, strength training (ST) would increase muscle power and size, thereby improving body composition, physical function, fatigue levels, and QoL in older black men with PCa. METHODS: Muscle mass, power, strength, endurance, physical function, fatigue perception, and QoL were measured in 17 black men with PCa on ADT before and after 12 weeks of ST. Within-group differences were determined using t tests and regression models. RESULTS: ST significantly increased total body muscle mass (2.7%), thigh muscle volume (6.4%), power (17%), and strength (28%). There were significant increases in functional performance (20%), muscle endurance (110%), and QoL scores (7%) and decreases in fatigue perception (38%). Improved muscle function was associated with higher functional performance (R (2) = 0.54) and lower fatigue perception (R (2) = 0.37), and both were associated with improved QoL (R (2) = 0.45), whereas fatigue perception tended to be associated with muscle endurance (R (2) = 0.37). CONCLUSIONS: ST elicits muscle hypertrophy even in the absence of testosterone and is effective in counteracting the adverse functional consequences of ADT in older black men with PCa. These improvements are associated with reduced fatigue perception, enhanced physical performance, and improved QoL. Thus, ST may be a safe and well-tolerated therapy to prevent the loss of muscle mass, strength, and power commonly observed during ADT.
Authors: E Oluwabunmi Olapade-Olaopa; Charles A Muronda; E Hugh MacKay; Alex P Danso; Davinder P Sandhu; Timothy R Terry; Fouad K Habib Journal: Prostate Date: 2004-06-01 Impact factor: 4.104
Authors: Astrid M Horstman; E Lichar Dillon; Randall J Urban; Melinda Sheffield-Moore Journal: J Gerontol A Biol Sci Med Sci Date: 2012-03-26 Impact factor: 6.053
Authors: Angela S Alberga; Roanne J Segal; Robert D Reid; Chris G Scott; Ronald J Sigal; Farah Khandwala; James Jaffey; George A Wells; Glen P Kenny Journal: Support Care Cancer Date: 2011-05-03 Impact factor: 3.603
Authors: James L Mohler; Kris E Gaston; Dominic T Moore; Michael J Schell; Brian L Cohen; Catharina Weaver; Peter Petrusz Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: T Hasenoehrl; M Keilani; T Sedghi Komanadj; M Mickel; M Margreiter; M Marhold; R Crevenna Journal: Support Care Cancer Date: 2015-05-24 Impact factor: 3.603
Authors: Chunliu Pan; Neha Jaiswal Agrawal; Yanni Zulia; Shalini Singh; Kai Sha; James L Mohler; Kevin H Eng; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk Journal: JCI Insight Date: 2020-03-26
Authors: Robert L Newton; William D Johnson; Chelsea Hendrick; Melissa Harris; Emanuel Andrews; Neil Johannsen; Ruben Q Rodarte; Daniel S Hsia; Timothy S Church Journal: Contemp Clin Trials Date: 2015-05-12 Impact factor: 2.226
Authors: Chunliu Pan; Shalini Singh; Deepak M Sahasrabudhe; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk Journal: Endocrinology Date: 2016-09-09 Impact factor: 4.736
Authors: Alanna Klose; Wenxuan Liu; Nicole D Paris; Sophie Forman; John J Krolewski; Kent L Nastiuk; Joe V Chakkalakal Journal: JCSM Rapid Commun Date: 2018